2024-09-10 15:54:43
Them European Medicines Agency (EMA) has recommended new measures to reduce important group effect of agranulocytosis, a known side effect caused by the drug metamizole, Nolotil. Agranulocytosis involves a sudden and sudden decrease in granulocytes, a type of white blood cell, which can cause serious or even fatal infections.
Medicines containing metamizole are prescribed in many EU countries for pain treatment moderate to intense fever. But still Its sale is prohibited in some 40 countries around the world.. Authorized uses vary from country to country and range from the treatment of pain after surgery or injury to the treatment of pain and fever related to crab.
Agranulocytosis is a known side effect of drugs containing metamizole can appear at any time during treatment or shortly after stopping taking the drug, and in people who have already taken metamizole without problems. This serious side effect was not related to the dose of metamizole.
That is, as EMA knows, with any dose, anyone can die due to the reduction of the defenses promoted by this drug, which is the most in Spain!
The EMA did not withdraw the drug
A review of metamizole has been initiated at the request of the Medicines Agency of Finland, because cases of agranulocytosis are still being reported with metamizole despite the recent strengthening of risk reduction measures in Finland.
After reviewing the data on the risk of agranulocytosis from metamizole, the European company decided that it is necessary to update the warnings in the product information… DO NOT remove the treatment from the product.
The EMA now recommends that healthcare professionals inform patients that they should stop taking Nolotil and seek medical attention immediately If they show symptoms of agranulocytosis. And what are these? Well, fever, cold, sore throat and painful sore on the soft inner surfaces of the body (mucosa), especially in the mouth, nose and throat or in the genital or anal areas. Patients should be alert for these symptoms both during and immediately after stopping treatment.
If metamizole is taken for fever, some early symptoms of agranulocytosis may not be noticed. Likewise, when used anti Together with metamizole, these symptoms can also be masked.
Stop treatment with Nolotil
If patients have symptoms of agranulocytosis, a test to measure blood cell levels, including levels of different types of white blood cells, should be done immediately. Him treatment should be stopped while waiting for results.
The EMA also recommends that metamizole not be used in patients with the risk of agranulocytosis increases or who are susceptible to it. This includes people who have previously experienced agranulocytosis caused by metamizole or similar drugs known to pyrazolones or pyrazolidineswho have problems with bone marrow.
The Agency’s recommendations arise from a review of all available evidence, including data from the scientific literature, post-marketing safety data, and information from interested parties such as patients and health professionals. It seems hard to believe that they have contacted all parties because if they knew it was There have been dozens of deaths in Spain for the use of the drug they will do more than give these recommendations discussed.
So the Agency again favored metamizole drug makers by concluding that its benefits “we are greater than the dangers«. The product information for all drugs containing metamizole will be updated with these recommendations, and the next meeting will be on the drug in September.
#European #Medicines #Agency #Nolotil #safe #ignores #deaths #caused